Yumanity Therapeutics (FRA:8IY) Cash-to-Debt : 41.26 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Yumanity Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2022 was 41.26.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Yumanity Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

The historical rank and industry rank for Yumanity Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:8IY's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.91
* Ranked among companies with meaningful Cash-to-Debt only.

Yumanity Therapeutics Cash-to-Debt Historical Data

The historical data trend for Yumanity Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Yumanity Therapeutics Cash-to-Debt Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Cash-to-Debt

1.01

2.42

1.32

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash-to-Debt	Get a 7-Day Free Trial							1.54	1.32	1.61	10.41	41.26

Competitive Comparison of Yumanity Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Yumanity Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yumanity Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's Cash-to-Debt falls into.

Yumanity Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Yumanity Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	32.303	/	(9.662	+	14.843)
	=	1.32

Yumanity Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.5	/	(0.206	+	0)
	=	41.26

Yumanity Therapeutics (FRA:8IY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Yumanity Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines